Giovanni Abbruzzese1, Jaime Kulisevsky2, Bruno Bergmans3, Juan C Gomez-Esteban4, Georg Kägi5, Jason Raw6, Alessandro Stefani7, Tobias Warnecke8, Wolfgang H Jost9. 1. DINOGMI, University of Genoa, Genova, Italy. 2. Sant Pau Hospital, Universitat Autònoma de Barcelona, CIBERNED, Barcelona, Spain. 3. Department of Neurology, AZ St-Jan Brugge-Oostende AV, Campus Brugge, Brugge & Ghent University Hospital, Ghent, Belgium. 4. Biocruces Research Institute, Barakaldo, Spain. 5. Department of Neurology, Cantonal Hospital St.Gallen, Switzerland. 6. Fairfield General Hospital, Bury, Greater Manchester, UK. 7. Parkinson Center, University Policlinico Tor Vergata, Roma, Italy. 8. Department of Neurology, University of Muenster, Muenster, Germany. 9. Parkinson-Klinik Ortenau, University of Freiburg, Wolfach, Germany.
Abstract
BACKGROUND: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. OBJECTIVE: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. METHODS: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbidities and with psychiatric conditions. RESULTS: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8% with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were those already described in the patients' information leaflet. The majority were mild or moderate and completely resolved and no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS motor score and in the UPDRS total score in ≥40% of patients, according to the criteria developed by Shulman et al. Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.
BACKGROUND:Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. OBJECTIVE: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. METHODS: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbidities and with psychiatric conditions. RESULTS: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8% with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were those already described in the patients' information leaflet. The majority were mild or moderate and completely resolved and no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS motor score and in the UPDRS total score in ≥40% of patients, according to the criteria developed by Shulman et al. Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.
Authors: Bruno Bergmans; Philip Bourgeois; Patrick Cras; Sophie Dethy; Nina De Klippel; Gianni Franco; Gaëtan Garraux; Karine Geens; Philippe Jacquerye; Anne Jeanjean; Frédéric Supiot; Chris Van der Linden; Claude Krygier Journal: Acta Neurol Belg Date: 2022-10-06 Impact factor: 2.471
Authors: Maria T Pellecchia; Marina Picillo; Maria C Russillo; Maria F De Pandis; Erminio Bonizzoni; Ivan Marjanovic; Carlo Cattaneo Journal: Front Neurol Date: 2021-12-14 Impact factor: 4.003
Authors: Fabrizio Stocchi; Angelo Antonini; Daniela Berg; Bruno Bergmans; Wolfgang Jost; Regina Katzenschlager; Jaime Kulisevsky; Per Odin; Francesc Valldeoriola; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2022-02-21
Authors: Giulia Ronconi; Silvia Calabria; Carlo Piccinni; Letizia Dondi; Antonella Pedrini; Immacolata Esposito; Alice Addesi; Luisa Sambati; Nello Martini Journal: Drugs Real World Outcomes Date: 2022-06-13
Authors: Diego Santos García; Carmen Labandeira Guerra; Rosa Yáñez Baña; Maria Icíar Cimas Hernando; Iria Cabo López; Jose Manuel Paz Gonález; Maria Gemma Alonso Losada; María José González Palmás; Cristina Martínez Miró Journal: Brain Sci Date: 2021-03-02